Guidelines on Urological Infections

[Pages:110]Guidelines on

Urological Infections

M. Grabe (chairman), T.E. Bjerklund-Johansen, H. Botto, B. Wullt, M. ?ek, K.G. Naber, R.S. Pickard, P. Tenke, F. Wagenlehner

? European Association of Urology 2012

TABLE OF CONTENTS

page

1.

INTRODUCTION

8

1.1 Background

8

1.2 Bacterial resistance development

8

1.3 The aim of the guidelines

8

1.4 Pathogenesis of UTIs

8

1.5 Microbiological and other laboratory findings

9

1.6 Methodology

9

1.6.1 Level of evidence and grade of guideline recommendations

10

1.6.2 Publication history

10

1.7 References

11

2.

CLASSIFICATION OF UTIs

12

2.1 Introduction

12

2.2 Level of infection

12

2.3 Grade of severity

13

2.4 Pathogens

14

2.5 Classification of UTI

14

2.6 Reference

14

3.

UNCOMPLICATED UTIs IN ADULTS

15

3.1 Summary and recommendations

15

3.2 Definition

15

3.2.1 Aetiological spectrum

15

3.3 Acute uncomplicated cystitis in premenopausal, non-pregnant women

15

3.3.1 Diagnosis

15

3.3.1.1 Clinical diagnosis

15

3.3.1.2 Laboratory diagnosis

15

3.3.2 Therapy

15

3.3.3 Follow-up

16

3.4 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women

16

3.4.1 Diagnosis

16

3.4.1.1 Clinical diagnosis

16

3.4.1.2 Laboratory diagnosis

16

3.4.1.3 Imaging diagnosis

16

3.4.2 Therapy

16

3.4.2.1 Mild and moderate cases of acute uncomplicated

pyelonephritis (Table 3.2)

17

3.4.2.2 Severe cases of acute uncomplicated pyelonephritis (Table 3.2)

17

3.4.3 Follow-up

18

3.5 Recurrent (uncomplicated) UTIs in women

20

3.5.1 Diagnosis

20

3.5.2 Prevention

20

3.5.2.1 Antimicrobial prophylaxis

20

3.5.2.2 Immunoactive prophylaxis

21

3.5.2.3 Prophylaxis with probiotics

21

3.5.2.4 Prophylaxis with cranberry

21

3.6 UTIs in pregnancy

21

3.6.1 Definition of significant bacteriuria

21

3.6.2 Screening

21

3.6.3 Treatment of asymptomatic bacteriuria

21

3.6.4 Duration of therapy

22

3.6.5 Follow-up

22

3.6.6 Prophylaxis

22

3.6.7 Treatment of pyelonephritis

22

3.6.8 Complicated UTI

22

3.7 UTIs in postmenopausal women

22

3.7.1 Risk factors

22

3.7.2 Diagnosis

22

2

UPDATE MARCH 2011

3.7.3 Treatment

23

3.8 Acute uncomplicated UTIs in young men

23

3.8.1 Men with acute uncomplicated UTI

23

3.8.2 Men with UTI and concomitant prostate infection

23

3.9 Asymptomatic bacteriuria

23

3.9.1 Diagnosis

23

3.9.2 Screening

24

3.10 References

24

4.

COMPLICATED UTIs DUE TO UROLOGICAL DISORDERS

28

4.1 Summary and recommendations

28

4.2 Definitions and classification

28

4.2.1 Clinical presentation

29

4.2.2 Urine cultures

29

4.3 Microbiology

29

4.3.1 Spectrum and antibiotic resistance

29

4.3.2 Complicated UTIs associated with urinary stones

29

4.3.3 Complicated UTIs associated with urinary catheters

29

4.4 Treatment

29

4.4.1 General principles

29

4.4.2 Choice of antibiotics

30

4.4.3 Duration of antibiotic therapy

30

4.4.4 Complicated UTIs associated with urinary stones

30

4.4.5 Complicated UTIs associated with indwelling catheters

31

4.4.6 Complicated UTIs in patients with spinal cord injury

31

4.4.7 Follow-up after treatment

31

4.5 References

32

5.

SEPSIS SYNDROME IN UROLOGY (UROSEPSIS)

33

5.1 Summary and recommendations

33

5.2 Background

33

5.3 Definition and clinical manifestation of sepsis in urology

34

5.4 Physiology and biochemical markers

35

5.4.1 Cytokines as markers of the septic response

35

5.4.2 Procalcitonin is a potential marker of sepsis

35

5.5 Prevention

35

5.5.1 Preventive measures of proven or probable efficacy (9,10)

35

5.5.2 Appropriate perioperative antimicrobial prophylaxis

36

5.5.3 Preventive measures of debatable efficacy

36

5.5.4 Ineffective or counterproductive measures

36

5.6 Algorithm for the management of urosepsis

36

5.7 Treatment

37

5.7.1 Clinical algorithm for management of urosepsis

37

5.7.2 Relief of obstruction

37

5.7.3 Antimicrobial therapy

37

5.7.4 Adjunctive measures (12,13)

37

5.8 Conclusion

37

5.9 Acknowledgement

38

5.10 References

38

6.

CATHETER-ASSOCIATED UTIs

39

6.1 Abstract

39

6.2 Summary of recommendations

40

6.3 Reference

41

7.

UTIs IN CHILDREN

41

7.1 Summary and recommendations

41

7.2 Background

41

7.3 Aetiology

42

7.4 Pathogenesis and risk factors

42

UPDATE MARCH 2011

3

7.5 Signs and symptoms

42

7.6 Classification

42

7.6.1 Severe UTI

43

7.6.2 Simple UTI

43

7.7 Diagnosis

43

7.7.1 Physical examination

43

7.7.2 Laboratory tests

43

7.7.2.1 Collection of the urine

43

7.7.2.1.1 Suprapubic bladder aspiration

43

7.7.2.1.2 Bladder catheterisation

43

7.7.2.1.3 Plastic bag attached to the genitalia

43

7.7.2.2 Quantification of bacteriuria

43

7.7.2.3 Other biochemical markers

44

7.7.2.3.1 Nitrite

44

7.7.2.3.2 Leukocyte esterase

44

7.7.2.3.3 C-reactive protein

44

7.7.2.3.4 Urinary N-acetyl-b-glucosaminidase

44

7.7.2.3.5 IL-6

44

7.7.3 Imaging of the urinary tract

45

7.7.3.1 Ultrasonography

45

7.7.3.2 Radionuclide studies

45

7.7.3.3 Cystourethrography

45

7.7.3.3.1 Conventional voiding cystourethrography

45

7.7.3.3.2 Radionuclide cystography (indirect)

45

7.7.3.3.3 Cystosonography

45

7.7.3.4 Additional imaging

45

7.7.3.5 Urodynamic evaluation

46

7.8 Schedule of investigation

46

7.9 Treatment

46

7.9.1 Severe UTIs

46

7.9.2 Simple UTIs

47

7.9.3 Prophylaxis

47

7.10 Acknowledgement

47

7.11 References

48

8. UTIs IN RENAL INSUFFICIENCY, TRANSPLANT RECIPIENTS, DIABETES MELLITUS AND

IMMUNOSUPPRESSION

52

8.1 Summary and recommendations

52

8.1.1 Acute effects of UTI on the kidney

52

8.1.2 Chronic renal disease and UTI

52

8.1.2.1 APCKD

52

8.1.2.2 Calculi and UTI

53

8.1.2.3 Obstruction of the urinary tract and UTI

53

8.1.3 UTI in renal transplantation and immunosuppression

53

8.1.4 Antibiotic treatment for UTI in renal insufficiency and after renal transplantation 53

8.2 Background

53

8.3 Acute effects of UTI on the kidney

53

8.3.1 VUR and intrarenal reflux

53

8.3.2 Obstructive neuropathy

53

8.3.3 Renal effects of severe UTI

54

8.3.4 Acute effects of UTI on the normal kidney

54

8.3.5 Renal scarring

54

8.3.6 Specific conditions in which an acute UTI causes renal damage

55

8.3.6.1 Diabetes mellitus

55

8.3.6.2 Tuberculosis

56

8.4 Chronic renal disease and UTI

56

8.4.1 Adult dominant polycystic kidney disease (ADPKD)

56

8.4.2 Renal calculi

56

8.5 UTI in renal transplantation

56

8.5.1 Donor organ infection

57

4

UPDATE MARCH 2011

8.5.2 Graft failure

57

8.5.3 Kidney and whole-organ pancreas transplantation

57

8.6 Antibiotic therapy in renal failure and transplant recipients

57

8.6.1 Treatment of UTI in renal transplant recipients

58

8.6.2 Fungal infections

59

8.6.3 Schistosomiasis

59

8.7 Immunosuppression

59

8.7.1 Human immunodeficiency virus (HIV) infection

59

8.7.2 Viral and fungal infections

59

8.8 References

59

8.8.1 Further reading

63

9.

URETHRITIS

63

9.1 Epidemiology

63

9.2 Pathogens

63

9.3 Route of infection and pathogenesis

63

9.4 Clinical course

63

9.5 Diagnosis

63

9.6 Therapy

63

9.6.1 Treatment of gonorrhoeal urethritis

63

9.6.2 Treatment of non-gonorrhoeal urethritis

64

9.7 Follow-up and prevention

64

9.8 References

64

10. PROSTATITIS AND CHRONIC PELVIC PAIN SYNDROME

65

10.1 Summary and recommendations

65

10.2 Introduction and definition

65

10.3 Diagnosis

66

10.3.1 History and symptoms

66

10.3.1.1 Symptom questionnaires

66

10.3.2 Clinical findings

66

10.3.3 Urine cultures and expressed prostatic secretion

66

10.3.4 Perineal biopsy

67

10.3.5 Other tests

67

10.3.6 Classification systems

68

10.3.7 Diagnostic evaluation

68

10.3.8 Additional investigations

68

10.4 Treatment

69

10.4.1 Antibiotics

69

10.4.2 Antibiotics and -blockers in combination therapy

69

10.4.3 Other oral medication

70

10.4.4 Intraprostatic injection of antibiotics

70

10.4.5 Surgery

70

10.4.6 Other treatment forms

71

10.5 References

71

11. EPIDIDYMITIS AND ORCHITIS

73

11.1 Summary and recommendations

73

11.2 Definition and classification

74

11.3 Incidence and prevalence

74

11.4 Morbidity

74

11.5 Pathogenesis and pathology

74

11.6 Diagnosis

74

11.6.1 Differential diagnosis

75

11.7 Treatment

75

11.8 References

75

12. SEXUALLY TRANSMITTED INFECTIONS

76

12.1 Reference

76

UPDATE MARCH 2011

5

13. FOURNIER'S GANGRENE

76

13.1 Summary of recommendations

76

13.2 Background

76

13.3 Clinical presentation

76

13.4 Microbiology

76

13.5 Management

77

13.6 References

77

14. SPECIFIC INFECTIONS

78

14.1 Urogenital tuberculosis

78

14.1.1 Reference

78

14.2 Urogenital schistosomiasis

78

14.2.1 Reference

78

15. PERIOPERATIVE ANTIBACTERIAL PROPHYLAXIS IN UROLOGY

78

15.1 Summary and recommendations

78

15.2 Introduction

80

15.3 Goals of perioperative antibacterial prophylaxis

80

15.4 Risk factors

81

15.5 Principles of antibiotic prophylaxis

82

15.5.1 Timing

82

15.5.2 Route of administration

82

15.5.3 Duration of the regimen

82

15.5.4 Choice of antibiotics

82

15.6 Prophylactic regimens in defined procedures

82

15.6.1 Diagnostic procedures

84

15.6.2 Endourological treatment procedures (urinary tract entered)

84

15.6.3 Laparoscopic surgery

84

15.6.4 Open or laparoscopic urological operations without opening of the urinary tract

(clean procedures)

85

15.6.5 Open or laparoscopic urological operations with open urinary tract (clean-

contaminated procedures)

85

15.6.6 Open urological operations with bowel segment (clean-contaminated or

contaminated procedures)

85

15.6.7 Postoperative drainage of the urinary tract

85

15.6.8 Implantation of prosthetic devices

85

15.5 Recommendations for perioperative antibiotic prophylaxis in urology

85

15.7 References

88

16. APPENDICES

94

16.1 Criteria for the diagnosis of UTI, as modified according to IDSA/European Society of

Clinical Microbiology and Infectious Diseases guidelines

94

16.1.1 References

94

16.2 Recommendations for antimicrobial therapy in urology

95

16.3 Recommendations for antimicrobial prescription in renal failure

96

16.4 Recommendations for perioperative antibiotic prophylaxis in urology

98

16.5 CPSI

100

16.6 Meares & Stamey localisation technique

101

16.7 Antibacterial agents

101

16.7.1 Penicillins

102

16.7.1.1 Aminopenicillins

102

16.7.1.2 Acylaminopenicillins

102

16.7.1.3 Isoxazolylpenicillins

102

16.7.2 Parenteral cephalosporins

103

16.7.2.1 Group 1 cephalosporins

103

16.7.2.2 Group 2 cephalosporins

103

16.7.2.3 Group 3a cephalosporins

103

16.7.2.4 Group 3b cephalosporins

103

16.7.2.5 Group 4 cephalosporins

103

16.7.2.6 Group 5 cephalosporins

103

6

UPDATE MARCH 2011

16.7.3 Oral cephalosporins

104

16.7.3.1 Group 1 oral cephalosporins

104

16.7.3.2 Group 2 oral cephalosporins

105

16.7.3.3 Group 3 oral cephalosporins

105

16.7.4 Monobactams

105

16.7.5 Carbapenems

105

16.7.6 Fluoroquinolones

105

16.7.6.1 Group 1 fluoroquinolones

106

16.7.6.2 Group 2 fluoroquinolones

106

16.7.6.3 Group 3 fluoroquinolones

106

16.7.7 Co-trimoxazole

106

16.7.8 Fosfomycin

106

16.7.9 Nitrofurantoin

107

16.7.10 Macrolides

107

16.7.11 Tetracyclines

107

16.7.12 Aminoglycosides

107

16.7.13 Glycopeptides

107

16.7.14 Oxazolidinones

107

16.7.15 References

107

16.8 Relevant bacteria for urological infections

109

17. ABBREVIATIONS USED IN THE TEXT

110

UPDATE MARCH 2011

7

1. INTRODUCTION

1.1 Background Urinary tract infections (UTIs) are among the most prevailing infectious diseases with a substantial financial burden on society. There are only limited data from Europe. In the USA, UTIs are responsible for over 7 million physician visits annually (1). Approximately 15% of all community-prescribed antibiotics in the USA are dispensed for UTI (2) and data from some European countries suggest a similar rate (3). In the US, UTIs account for more than 100,000 hospital admissions annually, most often for pyelonephritis (1). These data do apparently not account for complicated UTI associated with urological patients, the prevalence of which is not clear. UTIs represents at least 40% of all hospital acquired infections and are, in the majority of cases, catheter associated (4). Bacteriuria develops in up to 25% of patients who require a urinary catheter for one week or more with a daily risk of 5-7% (5,6). The recent Global Prevalence Infection in Urology (GPIU) studies have shown that 10-12 % of patients hospitalised in urological wards have a healthcare-associated infection (HAI). The strains retrieved from these patients are even more resistant (7).

1.2 Bacterial resistance development The present state of microbial resistance development is alarming (8). The use of antibiotics in the different countries and communities of Europe mirrors the global increase in resistant strains. There is a clear association between antibiotic use and the level of resistance on both individual and community levels (8). Multi-resistant microbial strains such as well known meticillin-resistant Staphylococcus aureus (MRSA) are found in an increasing number of patients. The presence of extended-spectrum b-lactamase producing E. coli (ESBL) showing resistance to most antibiotics, except for the carbapenem class, is steadily increasing in the population (9). Particularly troublesome is the increasing resistance to broad-spectrum antibiotics such as fluoroquinolones and cephalosorines. The microbes are harboured in the faecal reservoir and become a threat for urological patients in general, and men undergoing prostate biopsy in particular. The most important risk factors for this colonisation are recurrent infections and exposure to these antibiotics (10). Aggravating the situation is the observation of co-resistance to alternative antibiotics such as gentamicin (10). A strong grip on this threatening development is thus required. With few new antibiotics in the development chain, prudent use of antibiotics is the only option to delay the development of resistance (8). The urological community has a responsibility to engage in evidence-based practices regarding the use of antimicrobial agents. It is also essential to consider the local microbial environment and resistance pattern as well as each individual patient's risk factor for harbouring resistant strains.

1.3 The aim of the guidelines It is the ambition of the present guidelines to provide both urologist and physicians from other medical specialities with evidence-based guidance regarding the treatment and prophylaxis of UTI. These guidelines cover male and female UTIs, male genital infections and special fields such as UTI in paediatric urology, immunosuppression, renal insufficiency and kidney transplant recipients. Much attention is given to antibiotic prophylaxis, aiming to reduce the misuse and overuse of peri-operative prophylactic antibiotics. High quality clinical research using strict internationally recognised definitions and classifications as presented in this section are encouraged.

1.4Pathogenesis of UTIs Microorganisms can reach the urinary tract by haematogenous or lymphatic spread, but there is abundant clinical and experimental evidence to show that the ascent of microorganisms from the urethra is the most common pathway that leads to a UTI, especially organisms of enteric origin (e.g. E. coli and other Enterobacteriaceae). This provides a logical explanation for the greater frequency of UTIs in women than in men, and for the increased risk of infection following bladder catheterisation or instrumentation. A single insertion of a catheter into the urinary bladder in ambulatory patients results in urinary infection in 1-2% of cases. Indwelling catheters with open-drainage systems result in bacteriuria in almost 100% of cases within 3-4 days. The use of a closed-drainage system, including a valve to prevent retrograde flow, delays the onset of infection, but ultimately does not prevent it. It is thought that bacteria migrate within the mucopurulent space between the urethra and catheter, and that this leads to the development of bacteriuria in almost all patients within about 4 weeks.

Haematogenous infection of the urinary tract is restricted to a few relatively uncommon microbes, such as Staphylococcus aureus, Candida sp., Salmonella sp. and Mycobacterium tuberculosis, which cause primary infections elsewhere in the body. Candida albicans readily causes a clinical UTI via the haematogenous route, but is also an infrequent cause of an ascending infection if an indwelling catheter is present, or following antibiotic therapy.

The concept of bacterial virulence or pathogenicity in the urinary tract infers that not all bacterial

8

UPDATE MARCH 2011

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download